HFpEF is a unique and challenging set if pts which is a growing class in number. At one hand we have got for half of our HF population (HFrEF) to offer so much while at the same time the other unfortunate half (HFpEF) is begging for something with long-term benefits.
After being tested in animal studies current RCTs are in progress to test SGLT2i in HFpEF but would the peculiar mechanism of action of this medication especially favorable effects on DM, HTN, weight loss (risk factors for HFpEF) in addition to renal protective effect make us hopeful that this drug may prove to have mortality benefit even if only in a subset of HFpEF pts?
Or am I being too enthusiastic?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.